Merck & Co Inc

NYSE:MRK  
78.43
+0.65 (+0.84%)
4:32:17 PM EDT: $78.55 +0.12 (+0.15%)
Products

FDA Grants Priority Review To Merck’S Supplemental Biologics License Application For Keytruda® (Pembrolizumab)

Published: 12/17/2020 11:56 GMT
Merck & Co Inc (MRK) - FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for Keytruda® (pembrolizumab) Plus Chemotherapy As First-line Treatment for Locally Advanced Unresectable Or Metastatic Esophageal and Gastroesophageal Junction Cancer.
Merck & Co Inc - FDA Has Set PDUFA Or Target Action, Date of April 13, 2021.